<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>CXCL13/CXCR5 and CCL19/CCR7 play a quite important role in <z:mpath ids='MPATH_458'>normal</z:mpath> physiological conditions, but the functions of both chemokine/receptor pairs in pathophysiological events are not well-investigated </plain></SENT>
<SENT sid="1" pm="."><plain>We have investigated expression and functions of CXCL13/CXCR5 and CCL19/CCR7 in CD23+CD5+ and CD23+CD5- B cells from cord blood (CB) and patients with B cell lineage <z:hpo ids='HP_0011009'>acute</z:hpo> or <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> or B-CLL) </plain></SENT>
<SENT sid="2" pm="."><plain>CXCR5 and CCR7 are selectively expressed on <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>, B-CLL, and CB CD23+CD5+ B cells at high frequency, but not on CD23+CD5- B cells </plain></SENT>
<SENT sid="3" pm="."><plain>Although no significant chemotactic responsiveness was observed, CXCL13 and CCL19 cooperatively induce significant resistance to TNF-alpha-mediated <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> and B-CLL CD23+CD5+ B cells, but not in the cells from CB </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> and B-CLL CD23+CD5+ B cells express elevated levels of paternally expressed gene 10 (<z:chebi fb="0" ids="46550">PEG10</z:chebi>) </plain></SENT>
<SENT sid="5" pm="."><plain>CXCL13 and CCL19 together significantly up-regulate <z:chebi fb="0" ids="46550">PEG10</z:chebi> expression in the same cells </plain></SENT>
<SENT sid="6" pm="."><plain>We have found that CXCL13 and CCL19 together by means of activation of CXCR5 and CCR7 up-regulate <z:chebi fb="0" ids="46550">PEG10</z:chebi> expression and function, subsequently stabilize caspase-3 and caspase-8 in <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> and B-CLL CD23+CD5+ B cells, and further rescue the cells from TNF-alpha-mediated <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>Therefore, we suggest that <z:mpath ids='MPATH_458'>normal</z:mpath> lymphocytes, especially naive B and T cells, use CXCL13/CXCR5 and CCL19/CCR7 for migration, homing, maturation, and cell homeostasis as well as secondary lymphoid tissues organogenesis </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, certain malignant cells take advantages of CXCL13/CXCR5 and CCL19/CCR7 for infiltration, resistance to <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and inappropriate proliferation </plain></SENT>
</text></document>